Alamar Biosciences Q1 Revenue Nearly Doubles to $26M, Margin Hits 56%
Alamar Biosciences posted Q1 2026 revenue of $26.0M, up 99% year-over-year, driven by a 78% rise in instrument sales to $7.4M and 178% growth in consumable revenue to $14.0M. Gross margin improved to 56%, while cash and equivalents totaled $69.5M following its April IPO which raised approximately $220M.
1. Q1 2026 Revenue Growth
Alamar Biosciences generated $26.0 million in revenue during the first quarter of 2026, reflecting a 99% increase from $13.1 million last year. Instrument revenue rose 78% to $7.4 million, while consumable sales jumped 178% to $14.0 million and services revenue reached $4.7 million, up 20%.
2. Margin Expansion and Expenses
Gross margin expanded to 56%, up from 49% a year earlier, driven by manufacturing efficiencies, higher average selling prices and a favorable product mix. Operating expenses totaled $26.8 million, up 79% year-over-year, primarily due to increased personnel, product development and professional service costs, resulting in a $12.3 million operating loss and a $21.3 million net loss.
3. IPO Boosts Balance Sheet
In April 2026, Alamar Biosciences completed its initial public offering, raising approximately $220 million in gross proceeds and netting $197.8 million after expenses. As of March 31, 2026, the company held $69.5 million in cash, cash equivalents and restricted cash, providing funding for continued platform adoption and product expansion.
4. Guidance Timing
The company plans to issue full-year 2026 revenue guidance alongside its second quarter earnings release in August 2026, enabling investors to assess its growth trajectory and financial outlook for the remainder of the year.